Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally Mahmoud, Jian Li, Yuanxin Chen, Liangzhi Xie
Topics & Concepts
ImmunogenicityMedicineBooster doseBooster (rocketry)VaccinationVirologyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Bivalent (engine)2019-20 coronavirus outbreakClinical trialDouble blindImmunologyPlaceboImmunizationAntibodyInfectious disease (medical specialty)Internal medicineOutbreakDiseaseAstronomyMetalOrganic chemistryChemistryAlternative medicinePathologyPhysicsSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies